Kimio Sugaya Selected Research

naftopidil

1/2020	[Effects of alpha-1A/D adrenoceptor antagonist and phosphodiesterase type 5 inhibitor on bladder remodeling in rats with spinal cord injury].
12/2019	In Vitro Effects of Plasma Collected From Rats Administered Naftopidil on Whole Urinary Bladder Preparation Isolated From Rats.
8/2017	Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury.
5/2017	Naftopidil Improves Symptoms in a Rat Model of Tranilast-Induced Interstitial Cystitis.
5/2016	Influence of Naftopidil on Plasma Monoamine Levels and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
1/2016	Naftopidil improves locomotor activity and urinary frequency in rats with pelvic venous congestion.
5/2013	Effect of naftopidil, an alpha1D/A-adrenoceptor antagonist, on the urinary bladder in rats with spinal cord injury.
9/2010	Clinical Efficacy of α1-Adrenargic Receptor Antagonist Naftopidil 75 mg/day in Patients with Benign Prostatic Hyperplasia.
8/2002	Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kimio Sugaya Research Topics

Disease

15	Spinal Cord Injuries (Spinal Cord Injury) 01/2020 - 09/2003
8	Overactive Urinary Bladder (Overactive Bladder) 01/2021 - 12/2007
8	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2021 - 08/2002
6	Hyperemia 12/2019 - 01/2016
6	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 10/2019 - 10/2006
6	Body Weight (Weight, Body) 09/2011 - 03/2002
5	Lower Urinary Tract Symptoms 12/2019 - 11/2003
5	Nocturia 01/2018 - 11/2003
4	Stress Urinary Incontinence 01/2018 - 07/2008
4	Interstitial Cystitis (Interstitial Cystitis, Chronic) 05/2017 - 12/2002
4	Hyperoxaluria (Oxaluria) 06/2006 - 02/2003
3	Pain (Aches) 04/2021 - 11/2014
3	Fibrosis (Cirrhosis) 01/2020 - 05/2013
3	Urinary Incontinence 01/2018 - 03/2002
3	Underactive Urinary Bladder 01/2014 - 10/2007
3	Vitamin B 6 Deficiency (Pyridoxine Deficiency) 06/2006 - 02/2003
3	Neoplasms (Cancer) 03/2002 - 01/2002
2	Urge Urinary Incontinence (Urge Incontinence) 04/2021 - 01/2016
2	Constipation 01/2021 - 01/2018
2	Ischemia 01/2020 - 08/2017
2	Prostatitis 01/2016 - 11/2014
2	Abnormal Reflex (Hyperreflexia) 05/2013 - 12/2005
2	Ataxia (Dyssynergia) 09/2010 - 12/2005
2	Sneezing 10/2009 - 07/2008
2	Edema (Dropsy) 01/2008 - 04/2007
2	Neurogenic Urinary Bladder (Bladder, Neurogenic) 12/2007 - 03/2002
2	Prostatic Neoplasms (Prostate Cancer) 03/2004 - 03/2002
2	Hypertension (High Blood Pressure) 11/2003 - 09/2003
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2002 - 01/2002
1	Hyperalgesia 01/2022
1	Proximal Femoral Fractures 01/2021
1	Urologic Diseases (Urinary Tract Disease) 01/2021
1	Inflammation (Inflammations) 01/2019
1	Erythema 01/2018
1	Fatigue 01/2018
1	Urinary Retention 01/2018
1	Pelvic Pain 05/2017
1	Autonomic Dysreflexia 01/2017

Drug/Important Bio-Agent (IBA)

11	Glycine (Aminoacetic Acid)FDA LinkGeneric 04/2021 - 09/2003
9	naftopidilIBA 01/2020 - 08/2002
7	propiverineIBA 01/2019 - 10/2006
6	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2020 - 12/2002
6	Glutamic Acid (Glutamate)FDA Link 12/2019 - 01/2005
5	salicylhydroxamic acid (SHAM)IBA 12/2019 - 10/2007
4	Cholinergic Agents (Cholinergics)IBA 01/2019 - 01/2010
4	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2019 - 02/2007
4	Pharmaceutical PreparationsIBA 11/2014 - 03/2002
3	Messenger RNA (mRNA)IBA 01/2020 - 03/2008
3	Tadalafil (Cialis)FDA Link 01/2020 - 08/2017
3	gamma-Aminobutyric Acid (GABA)IBA 12/2019 - 03/2008
3	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 02/2007
3	Serotonin (5 Hydroxytryptamine)IBA 05/2016 - 02/2007
3	CatecholaminesIBA 10/2014 - 04/2007
3	distigmine (distigmine bromide)IBA 01/2014 - 01/2010
3	Calcium OxalateIBA 12/2009 - 02/2003
3	OxalatesIBA 02/2006 - 02/2003
2	Phosphodiesterase 5 InhibitorsIBA 01/2020 - 08/2017
2	CollagenIBA 01/2020 - 08/2017
2	ElastinIBA 01/2020 - 08/2017
2	BicucullineIBA 12/2019 - 03/2008
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 10/2016
2	tranilastIBA 05/2017 - 11/2013
2	Epinephrine (Adrenaline)FDA LinkGeneric 05/2016 - 02/2007
2	eviprostatIBA 01/2016 - 02/2008
2	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 09/2010 - 03/2008
2	EnzymesIBA 09/2010 - 05/2004
2	Adenosine Triphosphate (ATP)IBA 10/2009 - 02/2008
2	Serotonin ReceptorsIBA 10/2009 - 07/2008
2	Terazosin (Hytrin)FDA LinkGeneric 07/2008 - 11/2003
2	Amino Acids FDA Link 02/2007 - 12/2006
2	Alanine-glyoxylate transaminase (alanine-glyoxylate aminotransferase)IBA 06/2006 - 02/2003
2	AntigensIBA 03/2002 - 03/2002
1	Dinoprostone (PGE2)FDA Link 01/2022
1	HydrogenIBA 01/2021
1	Solifenacin Succinate FDA Link 01/2020
1	mirabegronIBA 01/2020
1	StrychnineIBA 12/2019
1	Taurine FDA Link 12/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Nitric Oxide Synthase Type I (Neuronal Nitric Oxide Synthase)IBA 01/2019
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2018
1	Therapeutic UsesIBA 01/2018
1	Muscarinic AntagonistsIBA 01/2018
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 08/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Capsaicin (Zostrix)FDA Link 01/2017
1	Liposomes (Liposome)IBA 01/2017
1	Nerve Growth Factor (NGF)IBA 01/2017
1	silodosin FDA Link 10/2016
1	8-Hydroxy-2'-DeoxyguanosineIBA 10/2016

Therapy/Procedure

7	Therapeutics 01/2018 - 03/2002
4	Renal Dialysis (Hemodialysis) 06/2007 - 07/2004
3	Prostatectomy (Retropubic Prostatectomy) 04/2009 - 03/2002
2	Oral Administration 12/2019 - 05/2013
2	Aftercare (After-Treatment) 01/2018 - 09/2010
2	Spinal Injections 05/2013 - 12/2005
2	Catheters 09/2011 - 06/2005
1	Urinary Catheters 01/2021
1	Ligation 10/2019
1	Anesthesia 01/2019